Sensitivity of primary myeloma cells to ABT-737
Patient . | Age, y . | Disease status . | LD50, nM . | % of cell death ABT-737 . |
---|---|---|---|---|
1 | 64 | Diagnosis | > 5000 | 8 |
2 | 80 | Diagnosis | < 100 | 62 |
3 | 78 | Diagnosis | < 20 | 90 |
4 | 69 | Diagnosis | 500 | 39 |
5 | 61 | Diagnosis | > 5000 | 12 |
6 | 47 | Diagnosis | 250 | 44 |
7 | 71 | Relapse | > 5000 | 28 |
Patient . | Age, y . | Disease status . | LD50, nM . | % of cell death ABT-737 . |
---|---|---|---|---|
1 | 64 | Diagnosis | > 5000 | 8 |
2 | 80 | Diagnosis | < 100 | 62 |
3 | 78 | Diagnosis | < 20 | 90 |
4 | 69 | Diagnosis | 500 | 39 |
5 | 61 | Diagnosis | > 5000 | 12 |
6 | 47 | Diagnosis | 250 | 44 |
7 | 71 | Relapse | > 5000 | 28 |
CD138+ purified myeloma cells were treated with various doses of ABT-737 during a 24-hour period. Cell viability was assessed, and the LD50 value was determined for each patient. In parallel, for each patient, we indicated the percentage of cell death upon ABT-737 treatment (100nM; 24 hours).